Efficacy and Safety of Task-specific, Biomarker-driven, HD-ctACS inTRD.

NCT07184697 · tracked via the Priya Life Science China tracker

Sponsor

Ruijin Hospital

Phase

Not applicable

Started

2025-08-14

Last updated

2025-09-22

Condition(s) studied

Major Depression

Investigational drug(s) / intervention(s)

HD ctACSHD ctACS sham

HD ctACS: Participants received High-Definition closed-loop transcranial Alternating Current Stimulation (HD-ctACS) for 30 minutes daily, 5 days per week. A 4x1 ring electrode montage was used, with the center electrode placed over the bilateral temporal cortices. Stimulation was delivered as a sinusoidal alternating current at a 2 mA peak amplitude, with the frequency individualized for each participant based on their baseline EEG. The stimulation was administered in a closed-loop, task-specific manner: a 500 ms burst of stimulation was triggered only when a subliminal negative facial stimulus was presented and the participant's real-time Nucleus Accumbens gamma power exceeded their baseline by two standard deviations.

HD ctACS sham: Participants received High-Definition transcranial Alternating Current Stimulation (HD-tACS) in 30-minute sessions once daily, 5 days per week. A 4x1 ring electrode layout was used to target the bilateral temporal cortices. The stimulation consisted of a sinusoidal alternating current with a 2 mA peak intensity, delivered at an individualized gamma frequency determined from a baseline EEG. The intervention was administered using a closed-loop, task-specific paradigm: upon presentation of a subliminal negative facial stimulus while the real-time Nucleus Accumbens gamma power exceeded a baseline threshold of +2 SD, a 500 ms stimulation was delivered following a random delay of 1000-2000 ms.

Study summary

This is a single-center, randomized, double-blind, sham-controlled, crossover exploratory clinical trial designed to evaluate the therapeutic effects of task-specific, biomarker-driven HD-ctACS on treatment-resistant depression (TRD). The study will enroll 10 patients diagnosed with TRD. Each participant will, in a randomized order, undergo a 4-week active HD-ctACS treatment period and a 4-week sham stimulation (delayed HD-ctACS) period, separated by an 8-week washout period. The primary objective is to assess the efficacy of HD-ctACS in improving core depressive symptoms, with the primary outcome being the difference in the Hamilton Depression Rating Scale (HAMD) total score between the end of the two intervention periods. Secondary objectives include evaluating the safety of the therapy, its effects on other symptom dimensions, and exploring its modulatory effects on neurobiological markers of emotional processing (e.g., NAc gamma power). The total participation time for each subject is approximately 16 weeks.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria Age between 18 and 65 years, any gender. Meets DSM-5 diagnostic criteria for Major Depressive Disorder (MDD), currently in a moderate to severe episode (total HAMD score ≥ 17). Meets the definition of Treatment-Resistant Depression (TRD): failure to respond to or intolerance of at least two antidepressant medications from different mechanistic classes, administered at an adequate dose and duration (e.g., 6-8 weeks) during the current depressive episode. Agrees to maintain a stable dosage of their current antidepressant medication regimen (if taking any) throughout the study period. Able to comprehend the study procedures and voluntarily provide written informed consent. Has intracranial deep brain electrodes implanted for research purposes, with electrodes located in the target brain regions (e.g., NAc, BNST). Exclusion Criteria History of other severe psychiatric disorders such as schizophrenia or bipolar disorder. Current severe suicide risk. History of alcohol or substance abuse/dependence (within the last year). History of epilepsy or has intracranial metal implants (other than the research electrodes). Presence of any unstable and significant somatic illness. Women who are pregnant or breastfeeding. Currently participating in another clinical trial.

Primary outcome measure(s)

Change from Baseline in Hamilton Depression Rating Scale 17-item (HAMD-17) Score — Baseline, Week 2, and Week 4 (End of Intervention).
The 17-item Hamilton Depression Rating Scale (HAMD-17) is a clinician-rated scale used to assess the severity of depression. The total score ranges from 0 to 52. A higher score indicates a worse outcome (i.e., greater depression severity).

Trial sites (1)

Facility	City	Region	Status
Ruijin Hospital	Shanghai	Shanghai Municipality

More Ruijin Hospital trials in China

Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy Recruiting

Clinical Analysis of the Antihypertensive Effect of Laparoscopic Peripheral Nerve Blockade of the Renal Artery in Patients With Retroperitoneal Disease and Hypertension Recruiting

The Effectiveness and Safety of TMF in the Treatment of Chronic Hepatitis B Patients With Normal ALT. Active, not recruiting

Directional PSA Versus STN DBS for TD-PD Recruiting

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer. Recruiting

Other trials for the same condition

Study on iTBS Regulating the Reward Circuit Function to Improve Anhedonia in Depression Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07184697 on ClinicalTrials.gov ↗ ← All trials in China